Basophil Activation Assay Using CD63 and CD32 Markers
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for determining the efficacy of allergen-specific desensitization treatments are inadequate, as they lack sensitivity, reliability, and reproducibility, and do not effectively distinguish between stable and transient responders.
Innovation Solution
An in vitro method that assesses the levels of both basophil activation markers, such as CD63, and basophil inhibitory markers, such as CD32, in a sample treated with an allergen, using a machine learning-supported evaluation and bin-based algorithm to determine the efficacy of the treatment.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current methods for determining treatment efficacy are used, then the assessment process is simple, but the sensitivity, reliability, and ability to distinguish between stable and transient responders are insufficient
Solution Approach 1:
The patent combines multiple markers (CD63 activation marker and CD32 inhibitory marker) into a single integrated assessment system. This merging of multiple measurement dimensions enables more reliable differentiation between stable and transient responders while maintaining a unified evaluation framework that does not excessively increase operational complexity
Solution Approach 2:
The patent introduces a dual-parameter assessment system measuring both CD63 and CD32 marker levels simultaneously. By changing from single-marker to multi-marker parameter measurement, the system achieves higher reliability in treatment efficacy assessment and can distinguish response stability without requiring complex procedural changes
2Measurement precision
If only basophil activation markers are measured, then the assessment method is simple, but the ability to accurately predict treatment efficacy and differentiate responders from non-responders is limited
Solution Approach 1:
The patent merges activation marker (CD63) and inhibitory marker (CD32) measurements into a single integrated assay system. This combination enables more precise prediction of treatment efficacy by capturing both activation and inhibition aspects of basophil response, while the markers are measured in the same sample under the same conditions, minimizing additional complexity
Solution Approach 2:
The CD32 inhibitory marker serves as an intermediary parameter that provides complementary information to the CD63 activation marker. By measuring both markers simultaneously, the system gains more precise insight into treatment response mechanisms, allowing better differentiation of responder types without requiring separate complex assay systems
Data Source
AI summary
An in vitro method for determining basophil activation in a sample is provided. Other aspects relate to determining an efficacy of an allergen-specific desensitization treatment of a subject. The method includes providing a sample from the subject, treating the sample with an allergen and determining a level of at least one basophil inhibitory marker and at least one basophil activation marker in the sample, the basophil inhibitory marker includes CD32. Corresponding systems and machine learning methods are also described. The use of an affinity reagent that specifically binds CD32 in an in vitro method for determining basophil activation is also provided, for example in the context of determining an efficacy of an allergen-specific desensitization treatment of a subject. A kit and corresponding uses of affinity reagents is also detailed.